Pharmacokinetic studies revealed an acceptable oral bioavailability and in vivo experiments showed a dose-dependent tumor growth inhibition, with induction of tumor necrosis, decreased expression of Ki67 and no signs of acute toxicity. Here, MKI67 is linked to neoplasm.